🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 2 días
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
14/01/2019 1,0700 USD
12/10/2018 0,9600 USD
12/07/2018 0,9600 USD
12/04/2018 0,9600 USD
11/01/2018 0,7100 USD
12/10/2017 0,6400 USD
12/07/2017 0,6400 USD
11/04/2017 0,6400 USD
11/01/2017 0,6400 USD
12/10/2016 0,5700 USD
13/07/2016 0,5700 USD
13/04/2016 0,5700 USD
13/01/2016 0,5700 USD
13/10/2015 0,5100 USD
13/07/2015 0,5100 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
25/01/2021 109,73 111,23 109,21 110,50 -0,32% 1,84% 6.928.200
22/01/2021 110,65 111,60 109,48 110,86 -0,36% 1,92% 5.185.500
21/01/2021 112,63 112,75 110,76 111,26 -1,21% 1,77% 5.417.000
20/01/2021 112,91 113,10 111,47 112,62 +0,39% 1,44% 6.554.600
19/01/2021 111,25 112,31 110,26 112,18 +1,50% 1,84% 7.723.800
15/01/2021 111,20 111,56 109,48 110,52 -0,99% 1,87% 9.196.200
14/01/2021 110,70 112,69 109,50 111,63 -0,73% 2,88% 8.268.800
13/01/2021 109,80 113,41 109,70 112,45 +2,43% 3,38% 9.821.300
12/01/2021 109,22 110,78 109,12 109,78 +0,70% 1,52% 6.106.900
11/01/2021 107,07 109,56 107,07 109,02 +1,63% 2,33% 6.334.200
08/01/2021 106,84 107,53 105,76 107,27 +0,52% 1,66% 5.345.900
07/01/2021 106,11 107,06 105,57 106,71 +1,07% 1,40% 8.196.000
06/01/2021 104,75 107,19 104,18 105,58 -0,86% 2,87% 11.017.500
05/01/2021 105,41 107,02 104,63 106,50 +1,03% 2,27% 6.823.800
04/01/2021 107,18 107,35 103,86 105,41 -1,62% 3,26% 9.523.400
31/12/2020 105,26 107,28 104,85 107,15 +1,79% 2,31% 6.148.100
30/12/2020 105,11 106,23 105,10 105,27 +0,54% 1,08% 5.328.400
29/12/2020 103,95 105,37 103,95 104,70 +1,21% 1,37% 5.096.400
28/12/2020 103,65 103,88 102,72 103,45 +0,18% 1,12% 3.948.900
24/12/2020 103,11 103,39 102,60 103,26 -0,02% 0,77% 1.378.600
23/12/2020 103,06 103,93 102,91 103,28 +0,47% 0,99% 3.659.100
22/12/2020 103,41 103,50 102,01 102,80 -0,88% 1,44% 4.002.900
21/12/2020 102,76 103,92 101,55 103,71 -0,71% 2,31% 6.664.600
18/12/2020 105,03 105,06 103,20 104,45 -0,42% 1,77% 13.906.800
17/12/2020 104,86 105,50 104,11 104,89 +0,24% 1,33% 6.360.600
16/12/2020 102,50 105,41 101,90 104,64 +1,77% 3,42% 9.182.100
15/12/2020 105,44 105,45 102,32 102,82 -1,32% 2,97% 12.101.000
14/12/2020 107,43 108,07 104,09 104,20 -2,01% 3,70% 8.272.700
11/12/2020 107,01 107,42 105,58 106,34 -1,07% 1,72% 5.205.200
10/12/2020 109,06 109,07 106,67 107,49 -1,09% 2,20% 6.285.700